Key features and details
- Mouse monoclonal [2059C4a] to BARD1
- Suitable for: Dot blot, WB, IP
- Reacts with: Human
- Isotype: IgG1
Product nameAnti-BARD1 antibody [2059C4a]
See all BARD1 primary antibodies
DescriptionMouse monoclonal [2059C4a] to BARD1
Tested applicationsSuitable for: Dot blot, WB, IPmore details
Species reactivityReacts with: Human
Recombinant fragment (Human)
- HEK293 whole cell lysate, RIPA lysate of HeLa cells.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term.
Storage bufferpH: 7.40
Preservative: 0.05% Sodium azide
Constituents: 1% BSA, PBS
Concentration information loading...
PurityProtein G purified
Purification notesProtein G purified from culture of supernatant of hybridoma cultured in a medium containing bovine IgG-depleted (~95%) fetal bovine serum. Filtered through a 0.22 µm membrane.
- Epigenetics and Nuclear Signaling
- DNA / RNA
- DNA Damage & Repair
- DNA Damage Response
- DNA Damage Recognition
- Cell Biology
- Proteolysis / Ubiquitin
- Proteasome / Ubiquitin
- Ubiquitin E3 Enzymes
- RING Finger E3 Ligase
Our Abpromise guarantee covers the use of ab50984 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|Dot blot||Use at an assay dependent dilution.|
|WB||1/50. Predicted molecular weight: 86 kDa.|
FunctionProbable E3 ubiquitin-protein ligase. The BRCA1-BARD1 heterodimer specifically mediates the formation of 'Lys-6'-linked polyubiquitin chains and coordinates a diverse range of cellular pathways such as DNA damage repair, ubiquitination and transcriptional regulation to maintain genomic stability. Plays a central role in the control of the cell cycle in response to DNA damage. Acts by mediating ubiquitin E3 ligase activity that is required for its tumor suppressor function. Also forms a heterodimer with CSTF1/CSTF-50 to modulate mRNA processing and RNAP II stability by inhibiting pre-mRNA 3' cleavage.
PathwayProtein modification; protein ubiquitination.
Sequence similaritiesContains 4 ANK repeats.
Contains 2 BRCT domains.
Contains 1 RING-type zinc finger.
modificationsProcessed during apoptosis. The homodimer is more susceptible to proteolytic cleavage than the BARD1/BRCA1 heterodimer.
Cellular localizationNucleus. During S phase of the cell cycle, colocalizes with BRCA1 into discrete subnuclear foci. Can translocate to the cytoplasm. Localizes at sites of DNA damage at double-strand breaks (DSBs); recruitment to DNA damage sites is mediated by the BRCA1-A complex.
- Information by UniProt
- BARD-1 antibody
- Bard1 antibody
- BARD1_HUMAN antibody
Anti-BARD1 antibody [2059C4a] (ab50984) at 1/50 dilution + HEK293 whole cell lysate at 50 µg
Anti mouse IgG antibody at 1/2500 dilution
Predicted band size: 86 kDa
Observed band size: 100 kDa why is the actual band size different from the predicted?
Ab50984 at 1/50 dilution precipitating RIPA lysate of HeLa cells at 500µg; visualised with anti mouse IgG antibody at 1/2500 diltuion.
ab50984 has been referenced in 1 publication.
- Stecklein SR et al. BRCA1 and HSP90 cooperate in homologous and non-homologous DNA double-strand-break repair and G2/M checkpoint activation. Proc Natl Acad Sci U S A 109:13650-5 (2012). WB . PubMed: 22869732